Roche wins Japan approval for personalised cancer drug Rozlytrek

Roche wins Japan approval for personalised cancer drug Rozlytrek
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann Copyright Arnd Wiegmann(Reuters)
By Reuters
Share this articleComments
Share this articleClose Button

ZURICH (Reuters) - Swiss drugmaker Roche on Tuesday won approval in Japan for Rozlytrek as the world's biggest maker of cancer drugs pushes ahead in personalised medicines that require a biomarker test to identify prospective patients.

Roche said Japan is the first country to approve Rozlytrek, also known as entrectinib, targeting people with NTRK fusion-positive solid tumours, across 10 different tumour types, including those with central nervous system metastases.

(Reporting by John Miller; Editing by Michelle Martin)

Share this articleComments

You might also like